Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes - PubMed
4 hours ago
- #Targeted Therapy
- #Non-Small Cell Lung Cancer
- #EGFR Mutations
- Afatinib and osimertinib show no significant differences in time to treatment failure or overall survival as first-line therapies for NSCLC with uncommon EGFR mutations.
- Afatinib is associated with higher response rates but more frequent adverse events requiring dose reduction compared to osimertinib.
- Treatment effects vary by mutation subtype: osimertinib favors L861X mutations, while afatinib favors compound mutations.
- Subsequent systemic therapy with immune checkpoint inhibitor plus platinum doublet offers limited additional benefit compared to platinum doublet alone.